RBP4 increases lipolysis in human adipocytes and is associated with increased lipolysis and hepatic insulin resistance in obese women
Open Access
- 1 May 2020
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 34 (5), 6099-6110
- https://doi.org/10.1096/fj.201901979RR
Abstract
Retinol-binding protein-4 (RBP4) is elevated in serum and adipose tissue (AT) in obesity-induced insulin resistance and correlates inversely with insulin-stimulated glucose disposal. But its role in insulin-mediated suppression of lipolysis, free fatty acids (FFA), and endogenous glucose production (EGP) in humans is unknown. RBP4 mRNA or protein levels were higher in liver, subcutaneous adipose tissue (SAT), and visceral adipose tissue (VAT) in morbidly obese subjects undergoing Roux-en-Y gastric bypass surgery compared to lean controls undergoing elective laparoscopic cholecystectomy. RBP4 mRNA expression in SAT correlated with the expression of several macrophage and other inflammation markers. Serum RBP4 levels correlated inversely with glucose disposal and insulin-mediated suppression of lipolysis, FFA, and EGP. Mechanistically, RBP4 treatment of human adipocytes in vitro directly stimulated basal lipolysis. Treatment of adipocytes with conditioned media from RBP4-activated macrophages markedly increased basal lipolysis and impaired insulin-mediated lipolysis suppression. RBP4 treatment of macrophages increased TNF alpha production. These data suggest that elevated serum or adipose tissue RBP4 levels in morbidly obese subjects may cause hepatic and systemic insulin resistance by stimulating basal lipolysis and by activating macrophages in adipose tissue, resulting in release of pro-inflammatory cytokines that impair lipolysis suppression. While we have demonstrated this mechanism in human adipocytes in vitro, and correlations from our flux studies in humans strongly support this, further studies are needed to determine whether this mechanism explains RBP4-induced insulin resistance in humans.Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK43051)
- Seventh Framework Programme (FP7‐EU 305707)
- Svenska Forskningsrådet Formas (350-2012-6616)
This publication has 48 references indexed in Scilit:
- Genome-wide analysis of FoxO1 binding in hepatic chromatin: Potential involvement of FoxO1 in linking retinoid signaling to hepatic gluconeogenesisNucleic Acids Research, 2012
- Retinol-Binding Protein 4 Inhibits Insulin Signaling in Adipocytes by Inducing Proinflammatory Cytokines in Macrophages through a c-Jun N-Terminal Kinase- and Toll-Like Receptor 4-Dependent and Retinol-Independent MechanismMolecular and Cellular Biology, 2012
- Insulin Regulates Adipocyte Lipolysis via an Akt-Independent Signaling PathwayMolecular and Cellular Biology, 2010
- Long-term Fenretinide treatment prevents high-fat diet-induced obesity, insulin resistance, and hepatic steatosisAmerican Journal of Physiology-Endocrinology and Metabolism, 2009
- Transcriptional activity of the murine retinol-binding protein gene is regulated by a multiprotein complex containing HMGA1, p54nrb/NonO, protein-associated splicing factor (PSF) and steroidogenic factor 1 (SF1)/liver receptor homologue 1 (LRH-1)The International Journal of Biochemistry & Cell Biology, 2009
- Adipose Tissue Exosome-Like Vesicles Mediate Activation of Macrophage-Induced Insulin ResistanceDiabetes, 2009
- Retinol-Binding Protein 4 in TwinsDiabetes, 2009
- Effect of Fenretinide and Low-Dose Tamoxifen on Insulin Sensitivity in Premenopausal Women at High Risk for Breast CancerCancer Research, 2008
- An RBP4 promoter polymorphism increases risk of type 2 diabetesDiabetologia, 2008
- Retinol Binding Protein 4 Expression in Humans: Relationship to Insulin Resistance, Inflammation, and Response to PioglitazoneJournal of Clinical Endocrinology & Metabolism, 2007